Mwyngil Therapeutics to tackle obesity, but without GLP-1s
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of…
Sales from controversial U.S. drug discount program rose to $100B last year
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Pharmalittle: RFK Jr. pushes against SSRIs, wearable drug okayed
Good morning, everyone, and welcome to another working week. And of course, it is nice to see you…
Kennedy presses ahead with plans to reduce antidepressant use
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Secret shopper study reveals questionable telehealth GLP-1 practices
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag…
Colorado’s first-of-its-kind price cap on an Amgen drug blocked
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Trump low-cost GLP-1 plan a likely boost for Eli Lilly, Novo Nordisk
WASHINGTON — The Trump administration’s grand bargain with drugmakers on GLP-1s was based on a simple premise: lower…
Nutex Health’s incredible rebound rests on two regulatory gray areas
Tara covers the business of health care. Her stories focus on hospitals, doctors, and how their business practices…
Pharmalittle: We’re reading about weight loss drug spending, launch prices for medicines, and much more
Top of the morning to you, and a fine one it is. Clear, blue skies and mild breezes…
Cadence raises $100 million to automate chronic disease care with regulated AI
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech;…
Definium LSD therapy for major depression helped patients in Phase 3 trial
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
2026 pharma and biotech deal-making already tops 2025 total
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of…